



SERVIZIO SANITARIO REGIONALE
EMILIA - ROMAGNA
Istituto Ortopedico Rizzoli di Bologna
Istituto di Ricovero e Cura a Carattere Scientifico



Preliminary Program

TARGETED PROTEIN DEGRADATION: *from biology to pharmacology*

4th June 2024
BOLOGNA

IRCCS Istituto Ortopedico Rizzoli
Centro di Ricerca Codivilla-Putti
Aula Marchetti

Via di Barbiano 1/10 - Bologna

Scientific Coordinators
Dr. Katia Scotlandi
Dr. Caterina Mancarella
Laboratory of Experimental Oncology
IRCCS Istituto Ortopedico Rizzoli

TARGETED PROTEIN DEGRADATION: *from biology to pharmacology*

Conference Aims

Targeted protein degradation is an emerging therapeutic modality based on the use of small molecules called degraders with the potential to tackle “undruggable targets” that have historically been highly challenging to target with conventional small molecules. Application of targeted protein degradation embraces experimental procedures based on engineered systems for ligand-induced protein degradation, computational and medical chemists, and rational design of novel therapeutic approaches.

This meeting will attract the interest of both basic and translational researchers, offering the opportunity to dive into the biggest challenges in early discovery and preclinical stages of targeted protein degradation. Joining a small but multidisciplinary group of academic and pharma discovery scientists with specific expertise in drug development and experimental modeling, attendees will learn how to identify new targets, discover novel ligands, and move them from early discovery to potential drug candidate. Interaction with speakers is favored to generate discussion, foster collaboration and knowledge exchange in the field of protein degradation.

Looking forward for meeting you, we welcome you in the lively city of Bologna, with its blend of fascinating culture, history, and delicious traditional food.

Caterina Mancarella
AICC CTS Member



Katia Scotlandi
AICC Past President



Michele Caraglia
AICC President



GENERAL INFORMATION

Conference Venue

IRCCS Istituto Ortopedico Rizzoli
Centro di Ricerca Codivilla-Putti
Aula Marchetti
Via di Barbiano 1/10, Bologna

Secretary AICC

aicc.meeting@gmail.com

Registration (VAT included)

Deadline: 28th May 2024

Meeting Registration fee: 75€

Reason for payment (causale):

please, indicate “your surname, name, TPD meeting registration”

Active AICC Membership fee: 50€

Reason for payment (causale):

please, indicate “your surname, name, 2024 AICC Membership”



*Please scan the QR code for meeting registration
or use the following link:*

<https://docs.google.com/forms/d/e/1FAIpQLSfWYKLgWvb3Hcp4sPmWWT8jWKcMHp0OnqZ5gR-irsbAnLlSQ/viewform?usp=sharing>

Bank transfer to:

Associazione Italiana di Colture Cellulari
IT97B0538703612000003002045
BPER BANCA S.P.A.
L'Aquila, agenzia 10,
Via Campo di Pile, 67100 L'Aquila (AQ)

Copy of the receipt must be sent to:

aicc.meeting@gmail.com

SCIENTIFIC PROGRAMME

09.30 | *Registration*

10.00 | OPENING CEREMONY
Greetings from Authorities
Greetings from AICC President

OPENING LECTURE

Chairs: Katia Scotlandi, Michele Caraglia

10.30 | Recruiting E3 ligases for targeted protein degradation: PROTACs, glues and everything in between.
Andrea Testa (*Amphista Therapeutics, Cambridge, UK*)

11.15 | *Coffee break*

Session I

PRECLINICAL MODELING AND CHALLENGES

Chairs: Chiara Riganti, Andrea Morandi

11.45 | Development of PROTAC targeting the RNA-binding protein IGF2BP3 in sarcoma.
Caterina Mancarella (*IRCCS Istituto Ortopedico Rizzoli*)

12.05 | PROTAC 101: how to develop drugs for undruggable targets.
Giuseppe Mancuso (*Promega Italia*)

12.25 | Molecular chameleonicity is an opportunity to discover new oral PROTAC drugs.
Giulia Caron (*University of Turin*)

12.40 | *To be defined*
Ciro Mercurio (*IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy*)

13.00 | *Light Lunch and Networking*

Session II

TARGETED PROTEIN DEGRADATION AS THERAPEUTIC TOOL: PROMISES AND CHALLENGES

Chairs: Maria Teresa Di Martino, Massimo Donadelli

- 14.00** Targeting Cyclin D1 with Folding Interfering Degraders, from Laboratory Research to Preclinical Development.
Simone Lanfredini (*Sibylla Biotech S.p.A.*)
- 14.30** Development of PROTACs: a new chemical modality for neurodegenerative and infectious diseases.
Maria Laura Bolognesi (*University of Bologna*)
- 15.00** *To be defined*
Frank Westermann (*German Cancer Research Center, Heidelberg, Germany*)
- 15.30** *Coffee break*

CLOSING LECTURE

Chairs: Francesca Zazzeroni, Enrico De Smaele

- 15.45** Challenges in the development of PROTAC
Gabriele Cruciani (*University of Perugia*)
- 16.15** *General Discussion and Closing Remarks*
- 16.45** *AICC General Assembly*

Scientific Coordinators

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

Katia SCOTLANDI

Caterina MANCARELLA

AICC Scientific Committee

President

Michele CARAGLIA

University of Campania “L. Vanvitelli”, Naples, Italy

Vice President

Francesca ZAZZERONI

University of L’Aquila, L’Aquila, Italy

Board of Directors

Chiara RIGANTI (*Secretary*)

University of Turin, Turin, Italy

Enrico DE SMAELE (*Treasurer*)

La Sapienza University of Rome, Rome, Italy

Massimo DONADELLI

University of Verona, Verona Italy

Maria Teresa DI MARTINO

“Magna Graecia” University, Catanzaro, Italy

Andrea MORANDI

University of Florence, Florence, Italy

Katia SCOTLANDI (*past President*)

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

Scientific Technical Committee

Daria CAPECE

University of L’Aquila, L’Aquila, Italy

Simone DI FRANCO

University of Palermo, Palermo, Italy

Alessandra FIORE

University of Verona, Verona, Italy

Joanna KOPECKA

University of Turin, Turin, Italy

Caterina MANCARELLA

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

Nicla LORITO

University of Florence, Florence, Italy

Silvia ZAPPAVIGNA

University of Campania "L. Vanvitelli", Naples, Italy

Pasquale ZIZZA

Regina Elena National Institute for Cancer Treatment and Research, Rome, Italy

Organizing Local Committee

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

Cristina FERRARI

Alessandra DE FEO

Evelin PELLEGRINI

Marianna CARRABOTTA

Lisa TORACCHIO

Faculty

Andrea TESTA

Amphista Therapeutics, Cambridge, UK

Caterina MANCARELLA

IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy

Giuseppe MANCUSO

Promega Italia

Giulia CARON

University of Turin, Italy

Ciro MERCURIO

IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy

Simone LANFREDINI

Sibylla Biotech S.p.A., Bresso, Italy

Maria Laura BOLOGNESI

University of Bologna, Italy

Frank WESTERMANN

German Cancer Research Center, Heidelberg, Germany

Gabriele CRUCIANI

University of Perugia, Italy

With the unrestricted grants of:

The Italian Ministry of Foreign Affairs and
International Cooperation and the Italian Ministry of Health within the
Executive Programme for Scientific and Technological Cooperation
between Italy and USA for the years 2023-2025 (MAECI-2023-23683465)

